Direct Impact

Concepts for which Han Phan has direct influence:

systemic corticosteroids
muscular dystrophy
ambulatory duchenne
zyn002 administered
pamrevlumab combination
transdermal gel
trial period

Prominent publications by Han Phan

KOL-Index: 7 Down syndrome (DS) is the most common genetic cause of intellectual disability and results from an extra chromosome 21 (Trisomy 21). Sleep issues and/or obstructive sleep apnea (OSA) are assumed to be part of the DS phenotype with a high prevalence but are often under recognized. This cross-sectional study of children with DS examines the caregiver-reported sleep behaviors of 108 children ...
Known for
Childrens Sleep Habit Questionnaire | Caregiver-Reported Sleep Behaviors | Issues Sleep | Children Syndrome
KOL-Index: 6 X-ray absorption spectroscopy (XAS) was utilized to gain insights into the structure and electronic properties of the reduced copper active site in NCU08746, a polysaccharide monooxygenase (PMO) from Neurospora crassa that activates O2 to cleave glycosidic linkages in starch. The reaction of NCU08746 likely starts with binding of O2 to the copper(I) center. However, the solution structure of ...
Known for
Copperi | Xas | Tyrosine Residue | Site Ncu08746
KOL-Index: 2 This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of Cannabidiol (CBD) administered as ZYN002 for the treatment of children and adolescent patients with Fragile X Syndrome (FXS). Eligible participants will participate in up to an 18 week treatment period, where all participants will receive placebo or active study drug. Patients ...
Known for
Proper Application | Trial Drug | Cgg Repeat | Transdermal Delivery
KOL-Index: 2 To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with systemic corticosteroids in subjects with non-ambulatory Duchenne muscular dystrophy (age 12 years and older). Detailed Description This is a global, randomized, double-blind trial of pamrevlumab or placebo in combination with systemic corticosteroids in subjects with non-ambulatory Duchenne muscular ...
Known for
Approved Products | Investigative Site | Safety Assessments | Systemic Steroids
KOL-Index: 2 To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with systemic corticosteroids administered every two weeks in ambulatory subjects with Duchenne muscular dystrophy (age 6 to <12 years). Detailed Description This is a global, randomized, double-blind, trial of pamrevlumab or placebo in combination with systemic corticosteroids in subjects with Duchenne muscular ...
Known for
Safety Assessments | Investigative Site | Potential Benefits | Approved Products

https://www.g2.com/products/key-opinion-leaders-kols/reviews https://www.bbb.org/us/fl/doral/profile/data-analytics/key-opinion-leaders-0633-92023858 https://www.trustpilot.com/review/keyopinionleaders.com https://www.yelp.com/biz/key-opinion-leaders-miami


© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172